Corbus Pharmaceuticals’ (CRBP) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated their buy rating on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $50.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $75.00. Several other research firms have also commented on CRBP. StockNews.com […]
